• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Hansa Biopharma AB (HNSA)

Sell: 32.14 SEK|Buy: 32.48 SEK|Change: 1.66 (-4.83%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Address




Website

https://www.hansabiopharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Hansa Biopharma AB Third Quarter Earnings Result for 20262026-10-22T00:00:00
Hansa Biopharma AB Third Quarter Earnings Conference Call for 20262026-10-22T00:00:00
Hansa Biopharma AB Second Quarter Earnings Result for 20262026-07-16T00:00:00
Hansa Biopharma AB Second Quarter Earnings Conference Call for 20262026-07-16T00:00:00
Hansa Biopharma AB Annual General Meeting for 20262026-06-25T14:30:00
Hansa Biopharma AB First Quarter Earnings Result for 20262026-04-23T00:00:00
Hansa Biopharma AB First Quarter Earnings Conference Call for 20262026-04-23T00:00:00
Hansa Biopharma AB Annual Report for 20252026-03-26T00:00:00
Hansa Biopharma AB Fourth Quarter Earnings Results for 20252026-02-05T00:00:00
Hansa Biopharma AB Fourth Quarter Earnings Conference Call for 20252026-02-05T00:00:00

Previous key dates

NameKey Date
DNB Nordic Healthcare Conference 20252025-11-25T00:00:00
Jefferies Global Healthcare Conference2025-11-18T00:00:00
SEB Healthcare Conference2025-11-13T00:00:00
Hansa Biopharma AB Third Quarter Earnings Conference Call for 20252025-10-30T08:00:00
Hansa Biopharma AB Third Quarter Earnings Result for 20252025-10-30T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T14:00:00
Hansa Biopharma AB Second Quarter Earnings Conference Call for 20252025-07-17T14:00:00
Hansa Biopharma AB Second Quarter Earnings Result for 20252025-07-17T00:00:00
Hansa Biopharma AB Annual General Meeting for 20252025-06-25T14:30:00
Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome2025-06-16T08:00:00
Hansa Biopharma AB First Quarter Earnings Conference Call for 20252025-04-24T14:00:00
Hansa Biopharma AB First Quarter Earnings Result for 20252025-04-24T00:00:00
Hansa Biopharma AB Annual Report for 20242025-03-21T00:00:00
Hansa Biopharma AB Fourth Quarter Earnings Conference Call for 20242025-02-06T14:00:00
Hansa Biopharma AB Fourth Quarter Earnings Result for 20242025-02-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.